Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.35 |
| ▸ | CHRNG | P07510 | 2/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CHRND | Q07001 | 2/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17391268 | 0.73 | CYP17A1 (0.34) | POLBALDH1A1CTSDBACE1BACE2 | |
| SCHEMBL15972683 | 0.68 | DRD2 (0.37) | KMT2AMEN1GAAMAPK1POLB | |
| SCHEMBL17345852 | 0.65 | LMNA (0.37) | OPRM1 | |
| SCHEMBL13003396 | 0.64 | — | — | |
| SCHEMBL9812155 | 0.63 | MAPT (0.40) | KMT2AMEN1GAAMAPK1ALDH1A1 | |
| SCHEMBL9812153 | 0.63 | MAPT (0.40) | KMT2AMEN1GAAMAPK1ALDH1A1 | |
| SCHEMBL2084415 | 0.61 | LMNA (0.54) | KMT2AMEN1MAPK1POLBELANE | |
| SCHEMBL15874277 | 0.60 | CHEK2 (0.43) | KMT2AMAPK1POLBALDH1A1CHRNA1 | |
| SCHEMBL22511149 | 0.60 | SIGMAR1 (0.36) | — | |
| SCHEMBL15341846 | 0.59 | CCR1 (0.36) | ALDH1A1CHRNA1CHRNGCHRNB1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | AMGEN INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-2958902-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014130470-A1 | CIS-MORPHOLINONE AND OTHER COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407721-B2 | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | MDM2, TP53, MDM4 | KMT2A 2836/4885MEN1 242/4885GAA 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.